Abiraterone vs Enzalutamide Among US Veterans With Metastatic Hormone-Sensitive Prostate Cancer

Do abiraterone and enzalutamide have comparable outcomes in patients with metastatic hormone-sensitive prostate cancer?In this cohort study using data from 1569 US veterans, those receiving abiraterone and enzalutamide had similar estimated rates of tumor growth and overall survival. These findings did not change after performing either inverse probability weighting or 1:1 exact matching.These findings suggest abiraterone and enzalutamide have comparable outcomes in patients with metastatic hormone-sensitive prostate cancer.

Corresponding Authors: Harshraj Leuva, MBBS, University of Nebraska Medical Center, 986840 Nebraska Medical Center, Omaha, NE 68198-6840 (hleuva@unmc.edu); Tito Fojo, MD, PhD, Columbia University Irving Medical Center, 161 Fort Washington Ave, 9th Floor, Room 936, New York, NY 10023 (atf2116@cumc.columbia.edu).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.